Alvarez M - Search Results

1

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. Lee JS, et al. Among authors: alvarez m. Mol Pharmacol. 1994 Oct;46(4):627-38. Mol Pharmacol. 1994. PMID: 7969041

2

Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.

Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE. Lai GM, et al. Among authors: alvarez mg. Int J Cancer. 1991 Nov 11;49(5):688-95. doi: 10.1002/ijc.2910490511. Int J Cancer. 1991. PMID: 1682279

3

Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate.

Bates SE, Currier SJ, Alvarez M, Fojo AT. Bates SE, et al. Among authors: alvarez m. Biochemistry. 1992 Jul 21;31(28):6366-72. doi: 10.1021/bi00143a002. Biochemistry. 1992. PMID: 1352990

4

Molecular targets in the National Cancer Institute drug screen.

Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, Chabner BA. Bates SE, et al. Among authors: alvarez m. J Cancer Res Clin Oncol. 1995;121(9-10):495-500. doi: 10.1007/BF01197759. J Cancer Res Clin Oncol. 1995. PMID: 7559726 Review. No abstract available.

5

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T. Alvarez M, et al. J Clin Invest. 1995 May;95(5):2205-14. doi: 10.1172/JCI117910. J Clin Invest. 1995. PMID: 7738186 Free PMC article.

6

Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.

Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, Fojo T. Alvarez M, et al. Mol Pharmacol. 1998 Nov;54(5):802-14. doi: 10.1124/mol.54.5.802. Mol Pharmacol. 1998. PMID: 9804615

7

Normal p53 status and function despite the development of drug resistance in human breast cancer cells.

Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE. Wosikowski K, et al. Among authors: alvarez m. Cell Growth Differ. 1995 Nov;6(11):1395-403. Cell Growth Differ. 1995. PMID: 8562478

8

Clinical reversal of multidrug resistance.

Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B. Bates SE, et al. Among authors: alvarez m. Stem Cells. 1996 Jan;14(1):56-63. doi: 10.1002/stem.140056. Stem Cells. 1996. PMID: 8820952 Review.

9

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Rixe O, et al. Among authors: alvarez m. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65. doi: 10.1016/s0006-2952(97)81490-6. Biochem Pharmacol. 1996. PMID: 8951344

10

Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.

Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Mickley LA, et al. Among authors: alvarez m. Blood. 1998 Mar 1;91(5):1749-56. Blood. 1998. PMID: 9473242 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,862 results

Search Page

Filters